Share Twitter LinkedIn Facebook Email Michelle Dawson, MD, AstraZeneca, talks about 75% Overall Response from Moxetumomab 41% of patients had complete response at Annual Meeting 2018.
CAR T-cell Therapy in CLL (chronic lymphocytic leukemia): Navigating the Landscape and Looking Ahead with Catherine Coombs, MD Chronic Lymphocytic Leukemia 3 Mins Read
Nitin Jain, MD Challenging case involving advanced B-cell lymphoblastic leukemia (BLL) from the CAR-T and Bispecifics Conference [2024] Chronic Lymphocytic Leukemia 3 Mins Read
Positive Outcomes & Tolerability Sonrotoclax + Zanubrutinib in TN-CLL/SLL – ASH 2023 Updates Chronic Lymphocytic Leukemia 1 Min Read
